In light of future clinical trials combining GLI and MEK5/ERK5 inhibitors, it will be equally important to identify possible biomarkers of activation of HH/GLI and MEK5/ERK5 pathways to identify the subset of cancers that will likely respond to such inhibitors and to monitor the efficacy of the therapy. Here, MAPK7 is linked to cancer.